Can gene therapy (telomerase/follistatin) reverse human aging?
Claim attributed to Liz Parrish (CEO, BioViva), with Libella Gene Therapeutics (Bill Andrews, CSO; Jeff Mathis, president) , Parrish self-administered experimental AAV gene therapy in 2015 in Colombia, outside regulatory oversight; she is CEO of the company selling the concept, so the sole subject is also the promoter. Libella offered a pay-to-participate phase 1 trial at $1,000,000 per patient, also in Colombia, led by a vascular surgeon with no gene-transfer expertise.
The biology is real in mice, but no controlled human trial shows gene therapy reverses (or even slows) aging. The only human "evidence" is a conflicted, unpublished sample of one, and the proposed mechanism is genetically tied to higher cancer risk in people.
Raising a blood telomere number in one self-experimenting CEO is not the same as making a human age backwards, and the gene you would switch on is the one most cancers already switch on.
What it’s supposed to target
- Telomerase (hTERT)
- Telomere length
- Follistatin / myostatin
- AAV gene delivery
Two genetic levers sit behind the claim. Telomerase (hTERT) rebuilds the protective telomere caps that shorten with each cell division, so the theory is that switching it back on resets a cellular clock and lets tissue keep renewing. The second, a follistatin construct, blocks myostatin to build muscle. In mice, Blasco's lab showed AAV-telomerase gene therapy could extend lifespan without obviously raising cancer in their models, a genuine result.
The human story is the cautionary part. Telomerase is exactly what most cancers switch on to become immortal, so forcing it system-wide is a real oncogenic gamble, and the headline human “evidence” is an n=1 self-experiment (Liz Parrish) with a contested telomere readout, no controls, performed outside regulatory oversight. A plausible mechanism with a serious built-in risk, sold through pay-to-participate offshore “trials” rather than controlled data.
Mechanism is theory, not proof. A plausible pathway explains why something might work, not whether it does. The verdict rests on the evidence below, not the elegance of the theory.
What would have to be true
Telomere attrition is a hallmark of aging (holds).
Re-lengthening telomeres via TERT delays or reverses aging in mammals (partial: shown as lifespan DELAY in mice, not reversal).
The same intervention reverses aging in humans (does not hold: no controlled human data).
It does so without raising cancer risk in humans (does not hold: human genetics links longer telomeres to higher cancer risk).
What the evidence actually shows
The mouse biology is real, but it is a delay, not a reversal, and it is not human evidence
The strongest support is the Blasco lab's AAV9-TERT work: a single tail-vein dose extended median lifespan +24% in 1-year-old mice and +13% in 2-year-old mice versus AAV9-eGFP controls, "without increasing cancer" in that experiment (EMBO Mol Med, 2012). But the authors frame this as "delay[ed] aging and increased longevity," not reversal, and it is mouse data. Gorski (Science-Based Medicine) notes the reassuring safety partly reflects a cancer-resistant context: standard Tert-transgenic mice showed increased spontaneous tumors, and aging is multifactorial (genomic instability, DNA damage), not telomeres alone.
The only human "evidence" is a sample of one, and the mechanism is tied to cancer in people
The entire human case is Liz Parrish's 2015 self-experiment (telomerase plus follistatin, administered offshore): n=1, uncontrolled, unblinded, never peer-reviewed or published after ~10 years, with the promoter and subject being the same person. Independent reporting (MIT Technology Review) quotes UT Southwestern's Jerry Shay on the risk of "activating a pre-cancerous cell" in people "65 and over," and Maria Blasco that "many more studies should be done" first. Human genetics points the same way: genetically longer telomeres causally raise lung adenocarcinoma risk (OR 2.87 per 1 kb, P=6.3x10^-15), undercutting the safety premise.
Studies, graded, and who paid
Blasco lab AAV9-TERT raised median lifespan +24% (1-yr mice) and +13% (2-yr mice) with no excess cancer in that study; peer-reviewed, independent.
No controlled human trial exists; the single self-experiment is uncontrolled, unpublished, and conflicted.
Unestablished and concerning: genetically longer telomeres causally raise some cancer risks; telomerase reactivation is a near-universal step in human cancers.
| # | Study | Type | Size | Funding / COI | Key limitations |
|---|---|---|---|---|---|
| 52 | Bernardes de Jesus & Blasco, AAV9-TERT in mice (EMBO Mol Med, 2012) | In vivo animal intervention (vector-group randomized) | 1-yr group n=52 (TERT 21/eGFP 14/dead-TERT 17); 2-yr group n=37 (TERT 23/eGFP 14) | Independent Spanish National Cancer Research Centre (CNIO); authors declared no conflict | Mice only; lifespan DELAY not reversal; no-cancer result partly mouse-specific (post-adult dosing, non-integrating diluted vector). |
| 1 | Zhang et al., telomere length and cancer, Mendelian randomization (Hum Mol Genet, 2015) | Human genetic epidemiology (Mendelian randomization) | Multi-consortium GWAS, tens of thousands across cancers | Independent NCI/NIH (GAME-ON), Wellcome Trust, Australian NHMRC | Genetic-proxy, not interventional; informs causal cancer risk, not telomerase-therapy safety directly. |
| 3 | Regalado, "Buyer beware of this $1M gene therapy for aging" (MIT Technology Review, 2019) | Investigative journalism / expert reporting | n/a (claimed 2-3 prospective patients; CRO said none enrolled) | , Independent journalism; subject venture was pay-to-participate ($1M/patient) | Reporting, not primary trial data; enrollment claims conflicted across sources. |
| 4 | Gorski, $1M phase 1 anti-aging gene therapy critique (Science-Based Medicine, 2019) | Physician-scientist critical analysis | n/a | Independent Independent academic medical commentary | Commentary, not new data; argues phase 1 tests safety only, so charging $1M is unjustified. |
| 6 | $1M anti-aging gene therapy raises ethical concerns (Genetic Literacy Project, 2019) | Science journalism (republished aggregation) | n/a | , Republished excerpt of Emily Mullin's OneZero piece; corroborating, not original | Aggregation, not independent reporting; confirms offshore/pay-to-play but not the cancer caveat. |
Unproven ≠ disproven
The favorable evidence is preclinical and the human risk genuinely unestablished, so for the aging-reversal claim this is untested-in-humans more than disproven. But the marketed "reversal" runs so far ahead of any human data, and the only human attempt is uninterpretable, that the headline claim is Unsupported.
Where claim and evidence diverge
Mice are not people: a lifespan delay in a vector-randomized mouse study does not show aging reversal in humans, and the lone human case (n=1, unpublished, self-promoted) cannot fill that gap.
The money trail
BioViva is a private company whose sole self-experiment subject is its own CEO; the result is self-generated and never published. Libella charged $1,000,000 per patient to join a safety-only phase 1 trial in Zipaquira, Colombia, with patients funding the study and bearing all risk.
Both ventures operated offshore to avoid FDA/EMA oversight. The legitimate underlying science (CNIO mouse work; NCI/NIH, Wellcome, NHMRC telomere-cancer genetics) was independently funded with declared no conflicts, and none of it claims human aging reversal.
The honest read
Telomerase gene therapy is a serious research area that extends lifespan in mice, but there is no controlled human evidence it reverses aging, and the mechanism is entangled with cancer risk in people. The claim rests on a conflicted sample of one and offshore marketing, not on data.
What would change this verdict
A peer-reviewed, controlled human trial showing gene therapy reverses validated aging biomarkers (or hard clinical/mortality endpoints) with adequate, multi-year safety follow-up.
Long-term human safety data showing telomerase gene therapy does not raise cancer incidence, ideally with independent replication outside the sponsor.
Sources
- Bernardes de Jesus B, Vera E, Schneeberger K, et al. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Mol Med. 2012;4(8):691-704.
- Zhang C, Doherty JA, Burgess S, et al. Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. Hum Mol Genet. 2015;24(18):5356-5366.
- Regalado A. Buyer beware of this $1 million gene therapy for aging. MIT Technology Review. Dec 6, 2019.
- Gorski D. Would you pay $1 million to enroll in a phase 1 clinical trial of an 'anti-aging' gene therapy? Science-Based Medicine. Dec 9, 2019.
- $1 million for anti-aging gene therapy? 'Dubious' treatment raises ethical concerns (republished from Emily Mullin, OneZero). Genetic Literacy Project. Dec 11, 2019.
People also ask
- Can telomerase gene therapy reverse aging in humans?
- No controlled human trial shows this. The only human evidence is a single uncontrolled, unpublished, conflicted self-experiment. The biology is real in mice, but a lifespan delay in mice does not show aging reversal in people.
- Does telomerase gene therapy work in animals?
- Yes, in mice. An independent, peer-reviewed Blasco lab study using AAV9-TERT raised median lifespan about 24 percent in one-year-old mice and 13 percent in two-year-old mice, with no excess cancer in that study. The human leap is what is unsupported.
- Is anti-aging gene therapy safe?
- Unestablished and concerning. Genetically longer telomeres causally raise some cancer risks, and telomerase reactivation is a near-universal step in human cancers. The gene you would switch on is the one most cancers already switch on.
- What was the BioViva and Libella gene therapy controversy?
- Both operated offshore to avoid FDA and EMA oversight. BioViva's sole subject was its own CEO, with results never published. Libella charged 1 million dollars per patient to join a safety-only phase 1 trial in Colombia, with patients funding the study and bearing the risk.
Part of our guide: Frontier longevity science, fact-checked
Caveat is journalism, not medical advice. We check public claims against published evidence; we don’t diagnose, treat, or tell you what to take.